How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

Journal of the National Cancer Institute

Volumn 88, Issue 12, 1996, Pages 779-781

  Eisenberger, M A ^a   Nelson, W G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EDITORIAL; HUMAN; PROSTATE CANCER; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURAMIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0029950084     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.12.779     Document Type: Editorial

References (0)